The World's Pharma Lords: Which Countries Buy & Sell the Most Drugs?

The pharmaceutical industry is incredibly valuable and is continuing to grow. But just how much of the world’s imports and exports involve pharmaceuticals? To understand the impact of the pharmaceutical industry on the world’s economy, we created two visualizations to demonstrate pharmaceutical imports and exports by country in 2018.

   The United States is, by far, the world’s biggest importer of pharmaceuticals at $99.7 billion. As the opioid crisis in the United States carries on, pharmaceutical companies are being scrutinized, as was demonstrated in the Johnson and Johnson settlement.

Store Atmospherics: Κρίσιμος παράγοντας επιτυχίας του φαρμακείου

Άρθρο  στο περιοδικό "ΦΑΡΜΑΚΕΥΤΙΚΟΣ ΚΟΣΜΟΣ"
 
Για να το διαβάσετε ή να το εκτυπώσετε πατήστε στην εικόνα

The top 10 drug launches of 2019

Angus Liu | Fiercepharma

Cancer is probably the most sought-after indication in the biopharma world, but it’s missing from 2019's class of top drug launches. Instead, treatments in immunology and rare genetic diseases have grabbed the limelight.

We considered two EvaluatePharma projections in January and February to rank this year’s top 10 drug launches by 2024 sales. At the top of the list is Alexion’s Soliris follow-up, Ultomiris, which nabbed an FDA nod at the end of 2018, two months ahead of its scheduled decision date.

As part of CEO Ludwig Hantson’s plan for Alexion to pivot away from ultrarare diseases and reach more patients, the biotech has priced Ultomiris at a 10% discount to Soliris and is aiming to convert 70% of Soliris patients to the improved therapy. Paroxysmal nocturnal hemoglobinuria (PNH), the current condition Ultomiris is approved in, is a rare disease that involves the immune system.

STP: Powering Marketing Success

pharmexec.com | Gary Lyon*

NASCAR followers will likely recognize the famous red oval logo of STP, originally an acronym for “scientifically treated petroleum”. As a gasoline additive, STP is designed to prolong engine life and improve performance. Could “STP” also be a proven boost to healthcare marketing effectiveness? This article briefly explores the role and impact of three elements — I would argue the most important elements — of marketing planning that drive business success: Segmentation, Targeting and Positioning.

Segmentation

Segmentation is the process of dividing large, diverse markets into smaller, more homogenous sub-groups on the basis of one or more differentiating criteria. Traditionally, these criteria have included demographic or psychographic (lifestyle) factors but attitudinal and behavioural factors are equally important. 

The top 15 pharma companies by 2018 revenue

FiercePharma | Eric Sagonowsky

The pharma industry is always in flux, but the big names always turn up near the top of yearly sales rankings. This year is no different, with Johnson & Johnson, Roche, Pfizer, Novartis and Merck & Co. taking the top 5 spots in Big Pharma companies by 2018 sales. 

In fact, the top 15 names are the same against prior year rankings, but the order has shifted. Last year’s No. 5, Sanofi, slipped to No. 7 as its sales sank almost 2% year over year. Gilead Sciences, famously under hepatitis C pricing pressure for years, sank even farther in 2018, slipping three positions to No. 13. 

On the flip side, Bristol-Myers Squibb climbed from No. 15 to No. 12. And if the company scores its massive Celgene buyout, it’ll be even higher next year. Adding Celgene’s $15 billion in 2018 revenue would have given BMS nearly $38 billion in annual sales, ranking it among the top 10 pharma companies by annual sales 

And next year’s ranking will see at least one entirely new entrant in Takeda. The Japanese biopharma recently scooped up Shire but hasn't released its combined financials for 2018 to make it eligible for the rankings. 

Forget thinking about 'the patient.' Pharma's shifting to consumer-centric marketing instead

FiercePharma | Beth Snyder Bulik

Pharma and healthcare aren't just thinking about patients anymore. They're thinking about customers.

It's a shift similar to what happened in the tech world in the late ‘80s, says Scott Rabschnuk, who leads Hill Holliday Health. He worked in technology industry marketing in the ‘90s, when tech companies still called the people they served “end users,” a patronizing term that suggested an industry dominated by experts with little interest in the humans at the end of the line, he said.

For pharma and healthcare marketers now, the tech industry's evolution from treating customers as a faceless mass of end users to considering their input as consumers can be translated to the shift these days toward addressing patients directly. Yesterday's patients, who only got pharma information filtered through their doctors, are today’s informed consumers who actively participate in their own healthcare—and shouldn't be ignored. Pharma marketers have had to become better at creating more consumer-marketing customer relationships, Rabshnuk said.

GENESIS Pharma: συνεργασία με την Amicus Therapeutics®

Την εμπορική συνεργασία με την Amicus Therapeutics ανακοίνωσε η Genesis Pharma για τη διάθεση της μιγαλαστάτης στην Ελλάδα, την Κύπρο, τη Ρουμανία και τη Βουλγαρία, την πρώτη από του στόματος χορηγούμενη θεραπεία και το πρώτο φάρμακο ιατρικής ακριβείας για τη νόσο του Fabry.

Η φαρμακευτική εταιρεία GENESIS Pharma, που δραστηριοποιείται στην ευρύτερη περιοχή της Νοτιοανατολικής Ευρώπης, ανακοινώνει ότι η διεθνής φαρμακευτική εταιρεία βιοτεχνολογίας Amicus Therapeutics, που δραστηριοποιείται στο πεδίο των σπάνιων και ορφανών νοσημάτων, της παραχωρεί τα αποκλειστικά εμπορικά δικαιώματα της μιγαλαστάτης στην Ελλάδα, την Κύπρο, τη Ρουμανία και τη Βουλγαρία.

Top 10 drugs losing exclusivity in 2019

FiercePharma | Eric Palmer Mar 4, 2019

Pharma companies do their best to fight off patent expirations and generic competition as long as possible to protect their big moneymakers. But this year looks like the end of the line for many of the industry's top brands.

Pfizer’s Lyrica, GlaxoSmithKline’s Advair, Roche’s Rituxan, Gilead’s Harvoni and many other drugs are slated or expected to face new generic competition this year. Each has navigated a different path to the patent cliff, but they'll all end up delivering a heavy financial blow to their makers. 

For several companies included in the list, new generic pressure is already here. Amgen, for instance, started dealing with competition for Neulasta and Epogen last year, thanks to biosimilars from Mylan, Coherus and Pfizer. It remains to be seen just how much—and how quickly—biosimilars will hurt the profitable brands.

Other drugs face more uncertainty as they lose some of their IP protections. Enbrel, for instance, is another profitable drug that's nearing the cliff, but Amgen executives recently said their court fight against would-be biosim rival Sandoz will take a while to play out, so it's uncertain when the drug could face competition.

No bigger lineup of drugs is facing copycats for the first time than the one at Roche. Executives for the cancer giant have told investors they're expecting U.S. competition in 2019 for Rituxan, Herceptin and Avastin. Together, the trio of cancer megablockbusters pulled in more than $10 billion in the U.S. last year, Roche reported, representing a huge target for biosim companies.

Pfizer’s Lyrica and Glaxo’s Advair are two household names making an appearance in this year's ranking—again. Pfizer was slated to lose Lyrica exclusivity at the end of last year, but the FDA blessed the drugmaker with a 6-month extension for testing the drug in a set of pediatric patients. Glaxo, for its part, will finally face new Advair competition after numerous delays among would-be copycats. Mylan just recently scored FDA approval for its generic, and the company launched it in February. 

Γιατί το φαρμακείο χρειάζεται Αποτελεσματικό Μάρκετινγκ περισσότερο από άλλες επιχειρήσεις

Άρθρο στο περιοδικό ΦΑΡΜΑΚΕΥΤΙΚΟΣ ΚΟΣΜΟΣ που μόλις κυκλοφόρησε.

https://docdro.id/jSQpTBK

ΕΟΦ: Νέα εγκύκλιος σχετικά με τη Διαφήμιση των Φαρμακευτικών Προϊόντων

Κατάργηση της υπ’ αρ. 96583/24-9-2019 προηγούμενης τροποποιητικής Εγκυκλίου.

Για να κατεβάσετε τη νέα εγκύκλιο πατήστε http://snip.ly/l0rr71